N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to comba...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00070/full |
| _version_ | 1818481021030498304 |
|---|---|
| author | Keizo eKanasaki Takako eNagai Kyoko eNitta Munehiro eKitada Daisuke eKoya |
| author_facet | Keizo eKanasaki Takako eNagai Kyoko eNitta Munehiro eKitada Daisuke eKoya |
| author_sort | Keizo eKanasaki |
| collection | DOAJ |
| description | Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease. |
| first_indexed | 2024-12-10T11:29:56Z |
| format | Article |
| id | doaj.art-812ec5d43aff4bbbb5f6699972de000a |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-10T11:29:56Z |
| publishDate | 2014-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-812ec5d43aff4bbbb5f6699972de000a2022-12-22T01:50:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122014-04-01510.3389/fphar.2014.0007075936N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesKeizo eKanasaki0Takako eNagai1Kyoko eNitta2Munehiro eKitada3Daisuke eKoya4Kanazawa Medical UniversityKanazawa Medical UniversityKanazawa Medical UniversityKanazawa Medical UniversityKanazawa Medical UniversityFibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00070/fullDiabetes Mellitusarbfibroblastkidney fibrosisACE-I |
| spellingShingle | Keizo eKanasaki Takako eNagai Kyoko eNitta Munehiro eKitada Daisuke eKoya N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes Frontiers in Pharmacology Diabetes Mellitus arb fibroblast kidney fibrosis ACE-I |
| title | N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| title_full | N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| title_fullStr | N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| title_full_unstemmed | N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| title_short | N-acetyl-seryl-aspartyl-lysyl-proline: A valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| title_sort | n acetyl seryl aspartyl lysyl proline a valuable endogenous anti fibrotic peptide for combating kidney fibrosis in diabetes |
| topic | Diabetes Mellitus arb fibroblast kidney fibrosis ACE-I |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00070/full |
| work_keys_str_mv | AT keizoekanasaki nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes AT takakoenagai nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes AT kyokoenitta nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes AT munehiroekitada nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes AT daisukeekoya nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes |